These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 34973063)

  • 1. Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance.
    Vulpis E; Loconte L; Peri A; Molfetta R; Caracciolo G; Masuelli L; Tomaipitinca L; Peruzzi G; Petillo S; Petrucci MT; Fazio F; Simonelli L; Fionda C; Soriani A; Cerboni C; Cippitelli M; Paolini R; Bernardini G; Palmieri G; Santoni A; Zingoni A
    J Extracell Vesicles; 2022 Jan; 11(1):e12176. PubMed ID: 34973063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing.
    Vulpis E; Loconte L; Cassone C; Antonangeli F; Caracciolo G; Masuelli L; Fazio F; Petrucci MT; Fionda C; Soriani A; Cerboni C; Cippitelli M; Santoni A; Zingoni A
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.
    Molfetta R; Quatrini L; Capuano C; Gasparrini F; Zitti B; Zingoni A; Galandrini R; Santoni A; Paolini R
    Eur J Immunol; 2014 Sep; 44(9):2761-70. PubMed ID: 24846123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.
    Kloss M; Decker P; Baltz KM; Baessler T; Jung G; Rammensee HG; Steinle A; Krusch M; Salih HR
    J Immunol; 2008 Nov; 181(10):6711-9. PubMed ID: 18981088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.
    Bedel R; Thiery-Vuillemin A; Grandclement C; Balland J; Remy-Martin JP; Kantelip B; Pallandre JR; Pivot X; Ferrand C; Tiberghien P; Borg C
    Cancer Res; 2011 Mar; 71(5):1615-26. PubMed ID: 21257710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activating NKG2D ligand MHC class I-related chain A transfers from target cells to NK cells in a manner that allows functional consequences.
    McCann FE; Eissmann P; Onfelt B; Leung R; Davis DM
    J Immunol; 2007 Mar; 178(6):3418-26. PubMed ID: 17339436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
    Petillo S; Capuano C; Molfetta R; Fionda C; Mekhloufi A; Pighi C; Antonangeli F; Zingoni A; Soriani A; Petrucci MT; Galandrini R; Paolini R; Santoni A; Cippitelli M
    Cell Death Dis; 2021 Sep; 12(9):836. PubMed ID: 34482362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.
    Carbone E; Neri P; Mesuraca M; Fulciniti MT; Otsuki T; Pende D; Groh V; Spies T; Pollio G; Cosman D; Catalano L; Tassone P; Rotoli B; Venuta S
    Blood; 2005 Jan; 105(1):251-8. PubMed ID: 15328155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
    Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
    Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
    Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer exosomes and NKG2D receptor-ligand interactions: impairing NKG2D-mediated cytotoxicity and anti-tumour immune surveillance.
    Mincheva-Nilsson L; Baranov V
    Semin Cancer Biol; 2014 Oct; 28():24-30. PubMed ID: 24602822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
    Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
    Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.
    Wu X; Tao Y; Hou J; Meng X; Shi J
    Neoplasia; 2012 Dec; 14(12):1178-89. PubMed ID: 23308050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
    Zingoni A; Vulpis E; Cecere F; Amendola MG; Fuerst D; Saribekyan T; Achour A; Sandalova T; Nardone I; Peri A; Soriani A; Fionda C; Mariggiò E; Petrucci MT; Ricciardi MR; Mytilineos J; Cippitelli M; Cerboni C; Santoni A
    Front Immunol; 2018; 9():926. PubMed ID: 29765374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
    Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
    BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.
    Salih HR; Antropius H; Gieseke F; Lutz SZ; Kanz L; Rammensee HG; Steinle A
    Blood; 2003 Aug; 102(4):1389-96. PubMed ID: 12714493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
    Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner.
    Du C; Bevers J; Cook R; Lombana TN; Rajasekaran K; Matsumoto M; Spiess C; Kim JM; Ye Z
    J Immunother Cancer; 2019 Aug; 7(1):207. PubMed ID: 31387641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.